Trial of new dengue vaccine begins recruitment for child participants in Singapore
SINGAPORE – A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine in children aged two to 17. Developed by US-based pharmaceutical firm MSD, V181 is a single-dose vaccine that aims to …